09.12.201512th Swiss Experimental Surgery SymposiumYou are hereEventsLife science events 12th Swiss Experimental Surgery Symposium
The launch of a network composed of the CERN, the EPFL and the two university hospitals will allow to connect specialists with advanced knowledge from very different and very complementary worlds and thus promote the emergence of new ideas and new approaches.Indeed, current medicine already uses several radioactive isotopes for the diagnosis or treatment of certain cancerous diseases. However, at CERN, the number of testable molecules is almost infinite and, thanks to the structure which has been launched, new materials can be tested for their biological effects.
Medtech Innovation Event - Sept 4 - Swiss Innovation Park Biel/Bienne04.09.2017Swiss Medtech, be-advanced and Switzerland Innovation Park Biel/Bienne organise the 3rd matchmaking event solely for...
Welcome To Health ValleyBuilding on skills honed over the centuries, western Switzerland has become a world leader in biotech.
Med Discovery SATherapeutics & Diagnostics, Proteins / PeptidesMed Discovery is a Swiss biopharmaceutical company dedicated to the discovery and the development of highly specific treatments for uro-genital cancers.
Our strategy is to develop protein drugs based on the optimization of natural proteins involved in the regulation of biological pathways.
To achieve this we are leveraging a unique in-house expertise in kallikreins, the biggest class of human proteases, combined with an international network in clinical urology.
Our proprietary technology platform to produce protease inhibitors allows Med Discovery to target cancers or other diseases where there is a lack of specific treatment.
Using this approach, Med Discovery intends to become a leading research and development biotech company in the uro-genital field, developing products both in-house and with appropriate partners.